{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:44:26Z","timestamp":1782823466684,"version":"3.54.5"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study assessed efficacy and safety of the fixed ratio combination iGlarLixi 100\/33 (insulin glargine 100\u2009U\/mL plus lixisenatide 33\u2009\u03bcg\/mL) in people with type 2 diabetes (PwT2D) in daily clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This non\u2010interventional, multicentre, prospective, single\u2010arm 24\u2010week study documented PwT2D with an HbA1c of 7.5%\u201310.0%, currently treated with a basal insulin supported oral therapy (BOT) in German primary care facilities, after the physician had decided to change treatment to iGlarLixi 100\/33, independent of study participation. Primary end\u2010point was the absolute change in HbA1c (%) from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 93 participants included, 70 comprised the full analysis set for efficacy assessment. Approximately 24 weeks after switching to iGlarLixi 100\/33 HbA1c (mean\u2009\u00b1\u2009standard deviation) changed from 8.52\u2009\u00b1\u20090.82% by \u22120.74\u2009\u00b1\u20090.81% to 7.74\u2009\u00b1\u20090.76%, FPG from 174.3\u2009\u00b1\u200944.6\u2009mg\/dL (9.67\u2009\u00b1\u20092.48\u2009mmol\/L) by \u221232.9\u2009\u00b1\u200946.3\u2009mg\/dL (\u22121.83\u2009\u00b1\u20092.57\u2009mmol\/L) to 141.4\u2009\u00b1\u200934.1\u2009mg\/dL (7.85\u2009\u00b1\u20091.89\u2009mmol\/L) and body weight from 104.3\u2009\u00b1\u200922.5\u2009kg by \u22123.0\u2009\u00b1\u20097.5\u2009kg to 101.3\u2009\u00b1\u200921.6\u2009kg (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Furthermore, use of DPP4 inhibitors was significantly reduced from 34.8% to 6.8% of participants. Derived (from 7\u2010point self\u2010measured plasma glucose) time in range (TIR) increased and time above range (TAR) decreased after 24\u2009weeks to target ranges (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Flash glucose monitoring data of 20 patients showed similar patterns for TIR and TAR, respectively, and a reduction in time below range (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). Hypoglycaemia events did not change significantly and were low in number. No severe hypoglycaemia was reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Modifying antiglycaemic treatment from a BOT regimen to iGlarLixi 100\/33 in suboptimal controlled PwT2D in daily clinical practice improved glycaemic control without increasing hypoglycaemia and with favourable body weight change.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.16161","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T04:14:18Z","timestamp":1736136858000},"page":"1526-1535","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and safety of\n                    <scp>iGlarLixi<\/scp>\n                    in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5654-7310","authenticated-orcid":false,"given":"Jochen","family":"Seufert","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center\u2014University of Freiburg, Faculty of Medicine University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6719-5223","authenticated-orcid":false,"given":"Tobias","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Medical Care Center, Metabolic Medicine Leipzig  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-5305","authenticated-orcid":false,"given":"Katrin","family":"Pegelow","sequence":"additional","affiliation":[{"name":"Sanofi\u2010Aventis Deutschland GmbH  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8134-7588","authenticated-orcid":false,"given":"Julia","family":"Kenzler","sequence":"additional","affiliation":[{"name":"Sanofi\u2010Aventis Deutschland GmbH  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-0302","authenticated-orcid":false,"given":"Martin","family":"Pfohl","sequence":"additional","affiliation":[{"name":"Medical Care Center Endocrinology and Diabetology  D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S006"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12927"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S009"},{"issue":"2","key":"e_1_2_10_6_1","first-page":"S162","article-title":"Praxisempfehlungen der Deutschen Diabetes Gesellschaft. Therapie des Typ\u20102\u2010Diabetes","volume":"18","author":"Landgraf R","year":"2023","journal-title":"Diabetol Stoffwechs"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2018.09.010"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1444"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0251"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14528"},{"key":"e_1_2_10_12_1","unstructured":"Bundes\u00e4rztekammer (B\u00c4K) Kassen\u00e4rztliche Bundesvereinigung (KBV).Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ\u20102\u2010Diabetes\u2014Langfassung. Version 3.0. 2023 [cited: 2024\u201006\u201014]. doi:10.6101\/AZQ\/000503www.leitlinien.de\/diabetes"},{"key":"e_1_2_10_13_1","volume-title":"Handbook of Psychology and Diabetes: a Guide to Psychological Measurement in Diabetes Research and Practice","author":"Bradley C","year":"1994"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1624"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/19322968221149041"},{"key":"e_1_2_10_16_1","unstructured":"Summary of product characteristics for Suliqua\u00ae.[cited: 2024\u201006\u201014].https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/suliqua\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-060852"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14844"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15609"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13952"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14549"},{"issue":"3","key":"e_1_2_10_22_1","first-page":"116","article-title":"Sulfonylureas for therapy of type 2 diabetes","volume":"45","author":"M\u00fcller UA","year":"2018","journal-title":"Arzneiverordnung in der Praxis"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01407-3"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13535"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01383-w"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2022.02.003"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14151"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15074"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13182"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00725-9"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01564-z"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15486"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1978974"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14822"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000409"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejsp.401"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16161","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.16161","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T08:50:26Z","timestamp":1771059026000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.16161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/dom.16161"],"URL":"https:\/\/doi.org\/10.1111\/dom.16161","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16161\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v1\/review6","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16161\/v2\/review4","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"2024-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}